New chief executive for Daiichi Sankyo Europe
pharmafile | July 10, 2012 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Daiichi Sankyo
Jan Van Ruymbeke has been appointed as the new chief executive of Daiichi Sankyo Europe from October.
Van Ruymbeke, from Belgium, will replace Reinhard Bauer, who is retiring after 10 years in this position. Van Ruymbeke will assume responsibility for the pharma company in October. Until the end of June, he had been the executive VP at Grünenthal for the company’s business in Latin America.
Van Ruymbeke started his pharma career at Cilag Belgium before accepting a position with Janssen, where he was in charge of infectious diseases and dermatology. In 1996, he became general manager of Janssen-Cilag Hungary. Four years later, he assumed the position of executive director Pharma & Country president at Novartis South Africa.
In 2005, Mr Van Ruymbeke (53) joined Grünenthal, where he served as head of Global Brand Management. Two years later, he was appointed managing director of the German pharma company’s Spanish subsidiary. He then became the managing director responsible for Spain and Portugal.
In July 2010, he was named executive VP of the Latin America strategic business unit. As part of these responsibilities, he joined the Group Operating Committee at Grünenthal Group.
Reinhard Bauer, outgoing chief executive, said: “We are really pleased that we were able to hire Jan Van Ruymbeke to be the next chief executive of Daiichi Sankyo Europe. He has an excellent understanding of the pharma industry. Thanks to his extensive experience in many countries, he is the ideal candidate to lead Daiichi Sankyo Europe’s internationally focused business.”
Related Content
AAX Biotech and Daiichi Sankyo partner to evaluate antibody therapeutics
AAX Biotech, a Swedish biotechnology company specialising in next-generation antibody therapeutics, has launched a strategic …
Merck and Daiichi Sankyo expand development and commericalisation agreement to include MK-6070
Daiichi Sankyo and Merck (known as MSD outside of the US and Canada) have announced …
AstraZeneca shares results from phase 3 TROPION-Lung01 trial
AstraZeneca has announced results from the phase 3 TROPION-Lung01 trial of AstraZeneca and Daiichi Sankyo’s …
